Bio Protech바이오프로테크

Bio Protech, a small KONEX-listed biosensor maker, shows no reported financials in the data and its shares are down 20% over the past year.

Bio Protech develops medical biosensor products based on its proprietary technology and is pursuing research and development for new products. The data includes a share price of ₩400 with a market value of about ₩7.0B, but no annual or trailing financial statements, so revenue and profit trends cannot be assessed from the pack. Valuation multiples and dividend history are also unavailable apart from a 0% dividend yield.

What stands out

• Shares closed at ₩400 on 2026-10-28, within a 52-week range of ₩279 to ₩660.
• Returns are -2.4% over one month, +2.8% over three months and -20% over one year.
• No foreign or institutional net flows are shown over the last 20 days, and foreign ownership is 0% now and 60 days ago.
• Recent filings are mostly investor relations events, a 5%+ holding report, insider shareholding report and convertible share conversion rights exercises, with convertible bond decisions amended in April and July.
• No news headlines are included in the data.

What to watch

• Whether the company files its annual or quarterly financial statements, since none are included in the data.
• Further conversion of convertible shares, which the filings show has happened in July and September and could affect the share count.
• Any progress on new biosensor product development, which the data does not describe in detail.